- Created on September 13, 2013
The Fathallah Lab is focused on the molecular biology of malignant gliomas. Dr. Fathallah's goal is to understand glioma motility and invasion and devise therapeutic methods.
Dr. Gray's laboratory focuses on Huntington’s disease, a rare and fatal genetic degenerative disorder. Her goal is to identify and understand mechanisms that contribute to Huntington’s disease pathology.
The King Lab interests have centered on mechanisms of growth factor and cytokine mRNA regulation in malignant gliomas, amyotrophic lateral sclerosis (ALS), and spinal cord injury. Dr. King is also interested in molecular signatures of ALS in skeletal muscle. His long term goals are: 1) to identify potential therapeutic targets for treating these diseases, and 2) to characterize biomarkers that may help in diagnosis and clinical monitoring.
The Limdi Lab's primary research focus is to elucidate genetic and environmental determinants of drug response, specifically those that are associated with toxicity and lack of efficacy. Her goal is to identify genetic and environmental predictors of anticoagulant and antiplatelet response and use this information to individualize therapy.
The Lu Lab focuses on amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease. He is interested in a network of RNA binding proteins and aberrant RNA processing in the pathogenesis of ALS.
The Nabors Lab studies the role of post-transcriptional regulation of gene expression in primary brain cancers. The lab is focused on RNA binding proteins and their ability to regulate cell growth, profliferation, and invasion.
Dr. Roberson’s primary interest is age-related memory disorders and neurodegenerative disease, including Alzheimer's disease and frontotemporal dementia.
Dr. Standaert's lab is interested in the pharmacology and neurochemistry of the basal ganglia and the mechanisms of Parkinson's disease and other conditions which produce abnormalities of movement.
Dr. Suswam’s lab is interested in growth factor gene regulation in malignant glioma; characterization of pathways utilized for suppression of key tumor suppressor molecules such as tristetraprolin (TTP), and the overall impact of suppression on tumor progression and chemotherapeutic responses; and how these regulatory pathways underline health disparities.
The Ubogu Lab, the Neuromuscular Immunopathology Research Laboratory, is interested in the molecular biology and physiology of the human blood-nerve barrier, as well as mechanisms of leukocyte trafficking into the peripheral nervous system in health and in immune-mediated disorders such as Guillain-Barre-syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, vasculitic neuropathy and neuropathies associated with human immunodeficiency virus infection.
The West Lab focuses on discovering the biochemical and genetic basis of neurological disorders such as Parkinson’s disease and autism spectrum disorders.
The Yacoubian Lab is focused on understanding the pathophysiology of Parkinson’s disease with the long-term goal of developing neuroprotective therapies.